## PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHOR	rty.			
To:	PCT			
Davies Collison Cave Level 15 ! Nicholson Street MELBOURNE VIC 3000	NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION (PCT Rule 44.1)			
Resp due 6/4/04	Date of mailing 2 3 JAN 2004 (day/month/year)			
Applicant's or agent's file reference 12381870/TDO/FMT	FOR FURTHER ACTION See paragraphs 1 and 4 below			
International application No.	International filing date			
PCT/AU2003/001634	5 December 2003			
Applicant THE CORPORATION OF THE TRUSTEES OF TH QUEENSLAND et al				
1. X The applicant is hereby notified that the international searce	h report has been established and is transmitted herewith.			
Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claim	ns of the international application (see Rule 46):			
When? The time limit for filing such amendments is normally two months from the date of transmittal of the international search report.				
Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35				
For more detailed instructions, see the notes on the accompanying sheet.				
2. The applicant is hereby notified that no international search report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.				
3. With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:				
the protest together with the decision thereon has be- request to forward the texts of both the protest and the	en transmitted to the International Bureau together with the applicant's ne decision thereon to the designated Offices.			
	plicant will be notified as soon as a decision is made.			
claim, must reach the International Bureau as provided itechnical preparations for international publication.  Within 19 months from the priority date, but only in respect of examination must be filed if the applicant wishes to post date (in some Offices even later); otherwise, the applicant must, within 20 months from the phase before those designated Offices.	n Rules 90bis. 1 and 90bis. 3, respectively, before the completion of the some designated Offices, a demand for international preliminary the entry into the national phase until 30 months from the priority the priority date, perform the prescribed acts for entry into the national			
In respect of other designated Offices, the time limit of 30 mon	ths (or later) will apply even if no demand is filed within 19 months.			
See the Annex to Form PCT/IB/301 and, for details about the applicable time limits, Office by Office, see the PCT Applicant's Guide, Volume II, National Chapters and the WIPO Internet site.				
Name and mailing address of the ISA/AU	Authorized officer			
AUSTRALIAN PATENT OFFICE				
PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustralia.gov.au	TERRY MOORE			
Facsimile No. (02) 6285 3929	Telephone No. (02) 6283 2632			

# PATENT COOPERATION TREATY

# **PCT**

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 12381870/TDO/FMT	/FMT ACTION (Form PC1/13/220) as well as, where approved		
International application No. PCT/AU2003/001634	International filing date ( 5 December 2003	(day/month/year)	(Earliest) Priority Date (day/month/year) 6 December 2002
QUEENSLAND et al			TE SISTERS OF MERCY IN
Article 18. A copy is being transmitted to	the international Bureau.	Searching Authority an	nd is transmitted to the applicant according to
This international search report consists of		and in this report	
X It is also accompanied by a c	opy of each prior art docume	an ened in this report.	
Link it was filed unless ath	erwise indicated under this i	item.	is of the international application in the language in
the international search	was carried out on the basis	s of a translation of the	international application furnished to this Authority
carried out on the basis of th	e sequence listing:		ernational application, the international search was
	ational application in writter international application in		n.
	y to this Authority in written		
furnished subsequentl	y to this Authority in compu	ter readable form.	
annlication as filed ha	s been furnished.		es not go beyond the disclosure in the international
the statement that the furnished	information recorded in com	puter readable form is	identical to the written sequence listing has been
2. X Certain claims were found	unsearchable (See Box I).		
3. Unity of invention is lacki			
4. With regard to the title,	the text is approved as	submitted by the appli	icant.
	A	olished by this Authorit	
DEC-205 (Ly 75) / DCL-1	intergenic splice vari	iants associated w	ith Hodgkin's disease, and uses thereof
5. With regard to the abstract,	the text is approved as	s submitted by the appl	icant .
	the text has been estal The applicant may, w submit comments to t	ithin one month from t	ule 38.2(b), by this Authority as it appears in Box III. he date of mailing of this international search report,
6. The figure of the drawings to be			f and the second
	as suggested by the a		X None of the figures
	L	failed to suggest a fig	
	because this figure be	etter characterizes the i	nvention

International application No.

PCT/AU2003/001634

Box I	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This inte	ernational search report has not been established in respect of certain claims under Article 17(2)(a) for the following
1.	Claims Nos:  because they relate to subject matter not required to be searched by this Authority, namely:
2.	Claims Nos: 1, 29 and 37-56 (all partially)  because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  See separate sheet.
3.	Claims Nos:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)
Box II	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This In	sternational Searching Authority found multiple inventions in this international application, as follows:
}	
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Rem	ark on Protest  The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

International application No.

PCT/AU2003/001634

TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet) Box III The inventors have identified intergenically spliced DEC-205/DCL-1 mRNAs, which encode the intact DEC-205 ectodomain together with an additional carbohydrate recognition domain, a transmembrane domain and a cytoplasmic domain derived from DCL-1. These DEC-205/DCL-1 intergenic splice variants were identified on Reed-Sternberg cells and thus have application in the therapy and investigation of Hodgkin's disease.

International application No.

PCT/AU2003/001634

				. 1	
A. (	CLASSIFICATION OF SUBJECT MATTER				
Int. Cl. 7;	C12N 015/12; A61P 035/00				
According to I	international Patent Classification (IPC) or	to both	national classification and IPC		
	FIELDS SEARCHED				
SEE ELECT	mentation searched (classification system follow RONIC DATABASE BOX BELOW				
SEE ELECT	RONIC DATABASE BOX BELOW		ent that such documents are included in the fields search	ed	
COMPANY OF THE PARTY OF THE PAR	A] [MEDLINE] [DGENE] [NCBI]: DG 5; C TYPE LECTIN; C TYPE LECTI	CE1: D	data base and, where practicable, search terms used) CL 1; DEC205; DEC 205; LY75; LY 75; LY EPTOR; SPLICE VARIANT; SV; INTERGE	MPHOCYTE NIC; SEQ ID	
C.	DOCUMENTS CONSIDERED TO BE REL	EVANT			
Category*	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.		
x	Database accession # BAB22377. U 228 amino acids. 15 February 2001. This sequence is 100% identical to S	Kawai	J et al.	40-42, 44, 46- 48, 50, 55, 56	
x	Database accession # BAB23242. U 219 amino acids. 15 February 2001. This sequence is 100% identical to 5	Kawai	J et al.	40-42, 44, 46- 48, 50, 55, 56	
X F	Further documents are listed in the con	tinuatio	on of Box C See patent family ann	ex	
which is not considered to be of particular and relevance or to earlier application or patent but published on or "X" document the international filing date come who claim(s) or which is cited to establish the publication date of another citation or other special wite reason (as specified).		ter document published after the international filing date or priority date do not in conflict with the application but cited to understand the principle theory underlying the invention ocument of particular relevance; the claimed invention cannot be outsidered novel or cannot be considered to involve an inventive step then the document is taken alone ocument of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to person skilled in the art ocument member of the same patent family			
	tual completion of the international search		Date of mailing of the international search report		
19 January				JAN 2004	
AUSTRALIA PO BOX 200 E-mail addres	illing address of the ISA/AU IN PATENT OFFICE , WODEN ACT 2606, AUSTRALIA ss: pct@ipaustralia.gov.au . (02) 6285 3929		Authorized officer  TERRY MOORE  Telephone No: (02) 6283 2632		

International application No.
PCT/AU2003/001634

C (Continua	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	·
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
x	Database accession # AAH05501. 1110055L24 Rik protein [Mus musculus]. 168 amino acids. 3 April 2001. Strausberg RL et al. This sequence is 99.5% identical to SEQ ID NO 8 over 168 amino acids.	40-42, 44, 46- 48, 50, 55, 56
P, X	Kato M et al (2003). Hodgkin's lymphoma cell lines express a fusion protein encoded by intergenically spliced mRNA for the multilectin receptor DEC-205 (CD205) and a novel C-type lectin receptor DCL-1. The Journal of Biological Chemistry 278(36) 34035-34041.  See the entire document.	1-56

International application No.

PCT/AU2003/001634

#### Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

### Continuation of Box No: I

The full scope of claims 1, 29 and 37-56 has not been searched because these claims are so inadequately supported by the description that a meaningful search is impossible.

The applicant's invention resides in the provision of intergenically spliced DEC-205/DCL-1 mRNA, termed 'DEC-205 SV' (see page 19, lines 17-22), which encodes the intact DEC-205 ectodomain together with an additional carbohydrate recognition domain, a transmembrane domain and a cytoplasmic domain derived from DCL-1. As such, the applicant is entitled to claims DEC-205 SV and uses thereof.

Claims 1, 29, 37-38 and 51-54 are directed towards any DEC-205 intergenic splice variant, and methods of using such splice variants. The specification does not provide an overarching principle whereby any intergenic splice variant of DEC-205 may be identified, it merely provides support for DEC-205/DCL-1 splice variants.

Claims 39, 41 and 45-50 are directed towards agents that modulate the activity of DEC-205 SV, and uses of these agents. These are not claims to uses of DEC-205 SV, these are claims to agents that inherently interact with DEC-205 SV, and which owe nothing to the teachings of the specification.

Claims 40, 42-44, 46-50, 55 and 56 Claims 55 and 56 are directed towards methods of using DCL-1, and claims 40, 42-44 and 46-50 are directed towards agents that modulate the activity of DCL-1, and uses of these agents. DCL-1 is an agent that is capable of modulating DEC-2005 SV.

The claims have been searched as far as they relate to DEC-205/DCL-1 splice variants, or DCL-1, or uses thereof.

# This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

# IMAGES ARE BEST AVAILABLE COPY.

OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.